Earnings Call Summary | Sight Sciences(SGHT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Sight Sciences(SGHT.US) Q1 2024 Earnings Conference
The following is a summary of the Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript:
以下是視力科學公司（SGHT）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Sight Sciences reported Q1 2024 revenue of $19.3 million, a record for their first quarter period, with 3% sequential increase from Q4 2023. Surgical Glaucoma revenue stood at $18.3 million, up 5% year-on-year. However, Dry Eye revenue decreased to $1 million, a decrease of 32% from Q1 2023. Notably, the company reduced its cash usage to $10.8 million in Q1 2024, from $17.7 million in Q1 2023.
Sight Sciences報告稱，2024年第一季度收入爲1,930萬美元，創下第一季度紀錄，較2023年第四季度連續增長3％。青光眼手術收入爲1,830萬美元，同比增長5％。但是，乾眼症收入下降至100萬美元，較2023年第一季度下降了32％。值得注意的是，該公司將其現金使用量從2023年第一季度的1,770萬美元減少到2024年第一季度的1,080萬美元。
Business Progress:
業務進展：
Sight Sciences observed increased utilization of their Surgical Glaucoma technologies over the previous quarter and Q1 2023. The company has strategic initiatives for market penetration and expansion in both Surgical Glaucoma and Dry Eye segments. For the Dry Eye segment, they aim for coverage decisions starting 2025 with TearCare. The company anticipates double-digit growth in the second half of 2024 and into 2025, and expects increasing active accounts throughout 2024, particularly for Surgical Glaucoma. Notably, increased investments are being made to support this anticipated growth.
Sight Sciences觀察到，與上一季度和2023年第一季度相比，其外科青光眼技術的利用率有所提高。該公司爲手術青光眼和乾眼領域的市場滲透和擴張制定了戰略舉措。對於乾眼症細分市場，他們的目標是從2025年開始通過TearCare做出保險決策。該公司預計，2024年下半年和2025年將實現兩位數的增長，並預計整個2024年的活躍賬戶將增加，尤其是外科青光眼的賬戶。值得注意的是，正在增加投資以支持這一預期的增長。
More details: Sight Sciences IR
更多詳情： 視覺科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。